NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 910.5 DKK | -0.72% |
|
+0.19% | +30.58% |
| 09:25am | Roche shares gain on obesity drug results from early-stage trial | RE |
| 06:41am | US Senate Committee Warns of Potential Healthcare Bankruptcy Due to Novo Nordisk's Wegovy | MT |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.56% | 1,166 M€ | +0.26% | - | |
| 0.56% | 607 M€ | +0.05% | - | |
| 0.47% | 205 M€ | -.--% | ||
| 0.43% | 242 M€ | +9.80% | ||
| 0.39% | 283 M€ | +20.26% | ||
| 0.29% | 391 M€ | +9.52% | - | |
| 0.26% | 0 M€ | 0.00% | - | |
| 0.24% | 34 M€ | +9.13% | - | |
| 0.18% | 306 M€ | +6.72% | - | |
| 0.18% | 39 M€ | +5.99% | - | |
| 0.17% | 20 M€ | +1.47% | - | |
| 0.15% | 105 M€ | +4.25% | - | |
| 0.13% | 34 M€ | +4.06% | - | |
| 0.12% | 17 M€ | +3.30% | - | |
| 0.09% | 234 M€ | +7.45% | - |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
917.1
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.58% | 595B | |
| +35.01% | 709B | |
| -2.60% | 367B | |
| +20.83% | 334B | |
| +5.69% | 289B | |
| +13.96% | 239B | |
| +9.23% | 211B | |
| -3.39% | 203B | |
| +10.77% | 171B | |
| +0.10% | 163B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S
